Talanta Open (Aug 2023)
Designing a unique molecular size-dependent approach for determining levamisole via synergizing Rayleigh Scattering response of Cilefa Pink B dye; application to bulk, dosage forms, and biofluids; method greenness evaluation
Abstract
Levamisole is an anti-helminthic agent employed medically to treat worm-causative disease, also used as an immune system modifying agent in rheumatic arthritis and as assistant therapy for treating the cancers of the head, colorectal, and neck regions. The first innovative size-dependent approach for levamisole drug analysis is described in this study. It is both efficient and environmentally benign. The drug was evaluated and validated using a green, one-pot, and direct size-dependent technique in this approach. An instant complex was created by combining levamisole and Cilefa Pink B in a mildly acidic medium. The fluorimetric investigation was based on the augmentation effect of levamisole on the Rayleigh scattering response amplitude of a biological dye (Cilefa Pink B) at 424 nm. which was related to produced complex's molecular size. Linearity ranged from 0.08 to 2.0 µg mL−1, with sensitivity limits of 0.023 and 0.069 µg mL−1, respectively. Analytical modulation of Levamisole-Cilefa Pink B complexes was done for all system parameters. In addition, the system was found to meet ICH criteria. Moreover, this technique successfully recovered the substance in the prescribed medicinal dosage forms. The created fluorimetric technique was also successfully employed to track the drug of interest in human biofluids, which was a significant accomplishment. Finally, an eco-scale was applied to recognize the designed method's environmental friendliness.
